Chemerin as a New Marker in Iraqi Newly Diagnosed Type 2 Diabetes Mellitus

Abstract

           Chemerin is a novel adipokine, suggested to be involved in insulin resistance in obesity and type 2 diabetes and may be an attractive candidate for assessing risk of atherosclerotic cardiovascular disease.             The aim of this study was to examine the role of chemerin as a new marker in newly diagnosed type 2 diabetes mellitus accompanied with obesity and study the effect of age and gender in chemerin concentration.             This study included 53 (24 male and 29 female) newly diagnosed type 2 diabetic patients who visited the National Diabetic Center, University of AL-Mustansiriyah. Those cases were referred to the Center during the period from November 2013 until the end of August 2014. They were subdivided according to body mass index; their age range was (38-52), and (35) healthy subjects were selected as a control group; they were well matched age with patients group. There was a significant increase in waist, waist/hip ratio, body mass index, fasting blood sugar, glycated hemoglobin, total cholesterol, triglycerides, low density lipoprotein cholesterol, C-peptide, homeostasis model assessment for insulin resistance 2, and chemerin levels in newly diagnosed diabetic patients as compared to the control, (P=0.0001). The results appear there was a significant decrease in high density lipoprotein cholesterol. A significant difference was found in serum chemerin levels among lean, overweight, and obese of newly diagnosed type 2 diabetic patients, (P=0.01).There was a significant positive correlation between serum chemerin versus fasting blood sugar, glycated hemoglobin, lipid profile except high density lipoprotein cholesterol, C-peptide, and homeostasis model assessment for insulin resistance 2, while there was a significant negative correlation between high density lipoprotein cholesterol and chemerin, (P<0.05). It can be concluded that high levels of serum chemerin found in newly diagnosed type 2 diabetic patients suggest that chemerin may play an important role in the pathogenesis of insulin resistance and type 2 diabetes mellitus.